ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:ABMD
  • CUSIP: 00365410
  • Web: www.abiomed.com
  • Market Cap: $5.92 billion
  • Outstanding Shares: 43,578,000
Average Prices:
  • 50 Day Moving Avg: $129.78
  • 200 Day Moving Avg: $118.80
  • 52 Week Range: $94.81 - $137.00
  • Trailing P/E Ratio: 116.14
  • Foreward P/E Ratio: 52.67
  • P/E Growth: 1.83
Sales & Book Value:
  • Annual Revenue: $445.3 million
  • Price / Sales: 13.30
  • Book Value: $10.37 per share
  • Price / Book: 13.10
  • EBIDTA: $96.12 million
  • Net Margins: 11.63%
  • Return on Equity: 12.35%
  • Return on Assets: 10.54%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 5.66%
  • Quick Ratio: 5.12%
  • Average Volume: 291,989 shs.
  • Beta: 0.51
  • Short Ratio: 4.82

Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) announced its earnings results on Thursday, May, 4th. The company reported $0.33 EPS for the quarter, meeting the Thomson Reuters' consensus estimate of $0.33. The business had revenue of $124.68 million for the quarter, compared to analysts' expectations of $122.82 million. ABIOMED had a return on equity of 12.35% and a net margin of 11.63%. The firm's revenue was up 32.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.24 earnings per share. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

5 analysts have issued 1 year price objectives for ABIOMED's shares. Their forecasts range from $145.00 to $170.00. On average, they anticipate ABIOMED's stock price to reach $152.00 in the next twelve months. View Analyst Ratings for ABIOMED.

What are analysts saying about ABIOMED stock?

Here are some recent quotes from research analysts about ABIOMED stock:

  • 1. According to Zacks Investment Research, "ABIOMED Inc. posted a stellar third quarter of fiscal 2017, beating the Zacks Consensus Estimate on both the counts. Over the past six months ABIOMED has outperformed the broader industry trends in terms of price performance. However, an unfavorable estimate revision trend for the current quarter indicates looming concern ahead of the stock. Intensifying competition in the niche markets is likely to mar the company’s prospects over the long haul. Although Abiomed’s significant international presence helps broaden its customer base, fluctuations in currency exchange rates may impact the company’s international sales. Nevertheless, the flagship Impella product line is a significant growth catalyst for the company." (1/30/2017)
  • 2. Jefferies Group LLC analysts commented, "We hosted ABMD management for a series of meetings. As can be expected for a company that is growing revenue 40%+ and for a stock that has increased 33% this year (after 137% last year), the discussions focused on the sustainability of the company’s growth prospects. The outlook remains very encouraging and we offer some observations below. ABMD remains a top pick. ABMD remains at top pick. There are few growth stories that rival ABMD for large, under penetrated markets; established reimbursement; and no appreciable competition. Since the first PMA approval five quarters ago, the company has seen US Impella revenue growth average 49%. The company still only sells about 15k pumps a year in the US despite a market opportunity that is over 200k, a penetration rate of just 7%." (8/9/2016)

Who are some of ABIOMED's key competitors?

Who owns ABIOMED stock?

ABIOMED's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Primecap Management Co. CA (0.00%), BlackRock Inc. (0.00%), Vanguard Group Inc. (0.00%), Wellington Management Group LLP (0.00%), Palo Alto Investors LLC (4.41%) and Baillie Gifford & Co. (0.00%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Granahan Investment Management Inc. MA, Next Century Growth Investors LLC, Scout Investments Inc., First Trust Advisors LP, Russell Investments Group Ltd., Vanguard Group Inc. and Capital Fund Management S.A.. Company insiders that have sold ABIOMED stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley and Michael R Minogue. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Baillie Gifford & Co., Brown Capital Management LLC, Renaissance Technologies LLC, Jennison Associates LLC, Champlain Investment Partners LLC, William Blair Investment Management LLC and American Century Companies Inc.. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ABIOMED stock cost?

One share of ABIOMED stock can currently be purchased for approximately $135.88.

Analyst Ratings

Consensus Ratings for ABIOMED (NASDAQ:ABMD) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $152.00 (11.86% upside)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/6/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$145.00MediumView Rating Details
3/30/2017Leerink SwannBoost Price TargetOutperform$140.00 -> $150.00LowView Rating Details
1/8/2017BTIG ResearchReiterated RatingBuy$170.00N/AView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/AView Rating Details
8/9/2016Jefferies Group LLCBoost Price TargetBuy$130.00 -> $145.00N/AView Rating Details
4/10/2016Benchmark Co.Reiterated RatingBuy$145.00N/AView Rating Details
10/30/2015Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$85.00N/AView Rating Details
10/29/2015Sterne Agee CRTReiterated RatingBuyN/AView Rating Details
8/17/2015CRT CapitalInitiated CoverageBuyN/AView Rating Details
8/14/2015StephensReiterated RatingOverweight$103.00 -> $128.00N/AView Rating Details
8/5/2015Northland SecuritiesBoost Price TargetMarket Perform$60.00 -> $80.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for ABIOMED (NASDAQ:ABMD)
Earnings by Quarter for ABIOMED (NASDAQ:ABMD)
Earnings History by Quarter for ABIOMED (NASDAQ:ABMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ABIOMED (NASDAQ:ABMD)
2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.77
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176$0.20$0.29$0.24
Q2 20173$0.22$0.24$0.23
Q3 20173$0.29$0.31$0.30
Q4 20172$0.32$0.32$0.32
Q1 20183$0.39$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.44$0.50$0.47
Q4 20183$0.50$0.59$0.54
Q1 20191$0.41$0.41$0.41
(Data provided by Zacks Investment Research)


Dividend History for ABIOMED (NASDAQ:ABMD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ:ABMD)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 92.67%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.24View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.00View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.00View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.00View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.00View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.00View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.40View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.00View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.60View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.00View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.00View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.00View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.00View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.00View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.00View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.00View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.00View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.00View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.00View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.04View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.00View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.90View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.00View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.40View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.00View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.98View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.40View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.00View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.00View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.90View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.00View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.00View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.40View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.20View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ABIOMED (NASDAQ:ABMD)
Latest Headlines for ABIOMED (NASDAQ:ABMD)
finance.yahoo.com logoCan This 2015 Medical IPO Inject New Life Into Its Stock?
finance.yahoo.com - May 24 at 3:15 PM
americanbankingnews.com logoMichael G. Howley Sells 18,279 Shares of ABIOMED, Inc. (ABMD) Stock
www.americanbankingnews.com - May 17 at 7:26 PM
americanbankingnews.com logoMichael G. Howley Sells 600 Shares of ABIOMED, Inc. (ABMD) Stock
www.americanbankingnews.com - May 11 at 12:04 AM
americanbankingnews.com logoInsider Selling: ABIOMED, Inc. (ABMD) Director Sells 13,500 Shares of Stock
www.americanbankingnews.com - May 10 at 10:44 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) COO Sells $2,781,412.50 in Stock
www.americanbankingnews.com - May 10 at 10:24 PM
finance.yahoo.com logoAbiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017
finance.yahoo.com - May 9 at 8:15 PM
nasdaq.com logoAbiomed (ABMD) Q4 Earnings Meet, Revenues Beat Estimates - Nasdaq
www.nasdaq.com - May 9 at 3:15 PM
americanbankingnews.com logoBrokers Offer Predictions for ABIOMED, Inc.'s Q2 2018 Earnings (ABMD)
www.americanbankingnews.com - May 8 at 11:34 AM
americanbankingnews.com logoABIOMED, Inc. to Post Q1 2018 Earnings of $0.40 Per Share, Jefferies Group Forecasts (ABMD)
www.americanbankingnews.com - May 8 at 11:14 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 6 at 12:35 AM
finance.yahoo.com logoEdited Transcript of ABMD earnings conference call or presentation 4-May-17 12:00pm GMT
finance.yahoo.com - May 5 at 8:17 PM
fool.com logoAbiomed, Inc. Pumps Out 33% Revenue Growth
www.fool.com - May 5 at 2:53 PM
seekingalpha.com logoABIOMED (ABMD) Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:16 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Issues Earnings Results
www.americanbankingnews.com - May 4 at 4:56 PM
globenewswire.com logoAbiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study - GlobeNewswire (press release)
www.globenewswire.com - May 4 at 3:16 PM
finance.yahoo.com logoAbiomed Announces Q4 FY 2017 Revenue of $124.7 Million, Up 33% Over Prior Year and Total Year Revenue of $445.3 Million, Up 35% Over Prior Year
finance.yahoo.com - May 4 at 3:16 PM
finance.yahoo.com logoAbiomed Announces First Patient Enrolled in STEMI DTU Feasibility Study
finance.yahoo.com - May 4 at 3:16 PM
finance.yahoo.com logoAbiomed meets 4Q profit forecasts
finance.yahoo.com - May 4 at 3:16 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $122.13 Million
www.americanbankingnews.com - May 4 at 2:20 PM
zacks.com logoMedical Product Stocks' Earnings Due on May 4: ABMD & More
www.zacks.com - May 3 at 3:19 PM
americanbankingnews.com logoABIOMED (ABMD) Given Daily News Sentiment Rating of 0.11
www.americanbankingnews.com - May 3 at 8:28 AM
americanbankingnews.com logo$0.33 EPS Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - May 2 at 9:08 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Scheduled to Post Quarterly Earnings on Thursday
www.americanbankingnews.com - May 2 at 7:24 AM
nasdaq.com logoHumana (HUM) Likely to Beat Q1 Earnings: Stock to Gain?
www.nasdaq.com - May 1 at 11:58 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Extremely Likely to Impact ABIOMED (ABMD) Share Price
www.americanbankingnews.com - April 30 at 10:08 AM
finance.yahoo.com logoDiagnostic Kit Maker Tests Resistance In Base; Gets Rating Upgrade
finance.yahoo.com - April 28 at 3:04 PM
americanbankingnews.com logoABIOMED (ABMD) Receives Media Impact Rating of 0.28
www.americanbankingnews.com - April 27 at 2:04 PM
thestreet.com logoWestell Announces General Availability Of NFPA-Compliant Battery Back-up Unit For Public Safety And FirstNet Signal Boosters
www.thestreet.com - April 26 at 3:24 PM
americanbankingnews.com logoABIOMED (ABMD) Earns Coverage Optimism Rating of 0.69
www.americanbankingnews.com - April 23 at 7:32 AM
americanbankingnews.com logoABIOMED (ABMD) Earning Positive News Coverage, Study Shows
www.americanbankingnews.com - April 20 at 7:31 AM
nasdaq.com logoAdd Up The Parts: FXH Could Be Worth $68
www.nasdaq.com - April 19 at 3:15 PM
americanbankingnews.com logoABIOMED (ABMD) Given Daily Media Sentiment Score of 0.14
www.americanbankingnews.com - April 16 at 7:28 AM
globenewswire.com logoAbiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification - GlobeNewswire (press release)
globenewswire.com - April 13 at 3:19 PM
finance.yahoo.com logoAbiomed Fourth Quarter Fiscal 2017 Earnings and Conference Call Notification
finance.yahoo.com - April 13 at 3:19 PM
americanbankingnews.com logoZacks: Analysts Expect ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $122.13 Million
www.americanbankingnews.com - April 13 at 1:48 PM
americanbankingnews.com logo Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Earnings of $0.34 Per Share
www.americanbankingnews.com - April 11 at 9:37 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 11 at 12:42 AM
americanbankingnews.com logoABIOMED, Inc. (ABMD) Raised to "Overweight" at Piper Jaffray Companies
www.americanbankingnews.com - April 6 at 8:28 PM
americanbankingnews.com logoLeerink Swann Increases ABIOMED, Inc. (ABMD) Price Target to $150.00
www.americanbankingnews.com - April 5 at 11:07 AM
americanbankingnews.com logoShort Interest in ABIOMED, Inc. (ABMD) Increases By 12.7%
www.americanbankingnews.com - April 4 at 2:57 PM
americanbankingnews.com logoLeerink Swann Reaffirms Outperform Rating for ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 30 at 10:07 PM
bizjournals.com logoAbiomed unveils expanded Danvers HQ as headcount soars
www.bizjournals.com - March 30 at 8:22 PM
finance.yahoo.com logoAbiomed Marks Grand Opening of Newly-Expanded Headquarters in Danvers, Massachusetts
finance.yahoo.com - March 30 at 3:16 PM
thestreet.com logoWestell Technologies To Webcast Presentation At The MicroCap Conference
www.thestreet.com - March 23 at 3:25 PM
finance.yahoo.com logo7 Stocks That Are Outperforming the Market
finance.yahoo.com - March 22 at 8:17 PM
americanbankingnews.com logoABIOMED, Inc. (ABMD) VP Sells $1,240,000.00 in Stock
www.americanbankingnews.com - March 21 at 7:16 PM
finance.yahoo.com logoFirst-Ever Presentation on Abiomed's Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Car...
finance.yahoo.com - March 21 at 7:55 AM
us.rd.yahoo.com logo4:11 am Abiomed reports late-breaking reseach Impella Quality Assurance Program improved survival and native heart recovery
us.rd.yahoo.com - March 20 at 5:19 AM
globenewswire.com logoFirst-Ever Presentation on Abiomed's Impella® Quality (IQ) Assurance Program ...
globenewswire.com - March 19 at 3:15 PM
finance.yahoo.com logoFirst-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session
finance.yahoo.com - March 19 at 3:15 PM



ABIOMED (ABMD) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff